You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
據報開拓藥業(09939.HK)新冠疫苗臨床試驗報告受質疑
阿思達克 05-14 10:59
開拓藥業(09939.HK)於上月25日公布在美國進行用於治療輕中症男性新冠肺炎患者的普克魯胺3期臨床測試已完成首位患者入組及給藥後,帶動股價急升。但《路透社》報道,開拓藥業首席臨床試驗研究員Zeid Kayali表示,自己沒有負責該臨床試驗,截至5月初開拓藥業亦根本沒有給任何患者服藥。

開拓藥業財務總監盧燕表示,Kayali只是臨床試驗研究員之一,不會就上月25日有關患者用藥的公告發表進一步評論,同時拒絕透露其他首席研究員或負責臨床試驗機構的資料,稱這是公司的機密資料。

根據開拓藥業在美國臨床試驗網站上發布的文件,Zeid Kayali確實是被列為首席臨床試驗研究員;同時許多藥廠亦會提供領導臨床試驗研究員的資料,以及負責測試的研究組織或醫療機構的名稱,以確保科學有效性及患者的安全。

開拓藥業在3月時公布於巴西進行的臨床測試結果,發現可降低92%患者死亡風險,但目前普克魯胺仍未有獲得監管部門批准,同時在巴西的臨床測試亦尚未經過同行審閱。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account